Efficacy and Safety of Ensartinib Combined With Anlotinib in Lorlatinib-Resistant ALK-Positive NSCLC

Clinical trial NCT07671560 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07671560
Sponsor: Qiming Wang
Status: NOT_YET_RECRUITING
Phase: Phase 4
Study type: INTERVENTIONAL

ALK-positive, Locally Advanced or Metastatic (TNM Stage IIIB-IV) Non-small Cell Lung Cancer That Has Developed Resistance to Prior Treatment With Lorlatinib

Start date: 2026-07-01
Primary completion: 2028-12-31
Enrollment: 80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.